Bristol Myers’ (BMY) Abecma Gets ODAC Votes for Label Expansion
ZacksBristol Myers’ (BMY) Abecma gets eight out of 11 votes from the FDA’s ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.